This past Wednesday, Attorney General Jeff Sessions made the announcement that White House counselor Kellyanne Conway will be the Trump administration’s go-to for opioid crisis efforts. This announcement has been met with both praise and criticism. Some say this appointment actually gives validity to the White House’s commitment to solving the ongoing opioid epidemic, while others see it as the exact opposite.
For a little background, Kellyanne Conway worked as a pollster before becoming Trump’s campaign manager during his run for the 2016 presidential nomination. Currently, Conway serves as a White House spokeswoman and Trump surrogate. She has been seen on countless panels discussing the biggest topics and politics. She absolutely has her work cut out for her, so can Kellyanne Conway compete?
The Kellyanne Cons and Pros
So can this infamous Trump advocate, the woman who practically accidentally coined the phrase “alternative facts” compete with the opioid crisis in America? Kallyanne Conway has become notorious for defending some of President Trump’s most flagrant and controversial “alternative facts” in the media. But in her defense, she also has said some things that seem to highlight important prospects for this problem.
So here are some things to consider when we talk about Kellyanne Conway being put in charge of the opioid epidemic.
Lack of Experience
One of the big problems with this appointment people are pointing out is the lack of experience. Critics say this appointment speaks to how little passion the current administration is actually putting into fighting the opioid crisis since Kellyanne Conway has no experience in public health or with drug policy.
But in a time where Americans seem to be putting more trust in people that don’t typically meet the description of “qualified” in hopes that an outsider might bring better results, it makes sense that a lot of people might still hope Kellyanne can do some good.
Yet, there are still those who aren’t so sure. Tom Synan, a police chief and member of the Hamilton County Heroin Coalition in Ohio tweeted in response to the announcement:
“Ummm… did we run out of Dr’s, cops, addiction specialists or people who are actually dealing with this on the street to lead this?”
As a first responder, Synan is one of many people who are frustrated with the current actions being taken.
“I don’t want to get involved in politics, but it seems like it is a political position … I think I would have gone out to the country and tapped into people who are national experts who are on the street who are literally dealing with this issue every day,”
It seems many on the front lines are not impressed with the Trump administration’s move to put Kellyanne Conway in charge of efforts to combat one of the worst drug problems in the nation’s history.
Publicity and Perception
During a press briefing about the Justice Department’s efforts to combat the crisis where the announcement was made, Sessions said President Donald Trump chose Kellyanne Conway to “change the perception” about opioids and reduce addictions and deaths.
According to Sessions, President Trump has made the epidemic “a top priority for his administration, including every senior official and Cabinet member.”
An opioid policy expert Andrew Kolodny of Brandeis University actually defended the move when speaking to BuzzFeed News, stating:
“It is a positive sign. She is a high-profile figure in the administration, showing the administration takes this seriously,”
Some believe this can offer a sign of hope for more concrete action since many recovery advocates say despite the declaration of a public health emergency from President Trump there has been very little action taken to change the state of the epidemic.
Bertha Madras, a member of the President’s Commission on Combating Drug Addiction and the Opioid Crisis and Harvard Medical School professor, said:
“The most important thing that Kellyanne Conway will provide is access … but also commitment… She was at all the meetings, she listened and took copious notes.”
Let’s hope those are some good notes because thus far the opioid problem in America has shown no signs of slowing down. Jeff Sessions justified the appointment by saying Kellyanne Conway “understanding messaging” and can help turn around public perception. But is this about publicity, or is it about the preservation of life?
Surely breaking the stigma and changing the way addiction is viewed does matter, but should someone who specializes in making things look good to be in charge of how this country deals with one of the most prominent crises we face?
Treatment and Resources
Kellyanne does seem to support treatment, but to what extent it is still unclear. In one interview with ABC Kellyanne Conway did say,
“Pouring money into the problem is not the only answer. We have to get serious about in-facility treatment and recovery.”
So she at least appears to understand how crucial effective inpatient treatment is for recovery.
But when reporters mentioned the fact that there needs to be funding for these programs, she put more emphasis on “a 4 letter word called will” that seems to side-step the question- where will these resources come from?
As it now stands, White House has:
- Left the leadership role of the Office of National Drug Control Policy vacant
- Failed to release any written opioid-control strategy
- Not requested funds to replenish the national public health emergency fund that currently sits at just $66,000
In fact, President Trump’s 2018 budget request would increase addiction treatment funding by less than 2%. And don’t be fooled, that increase includes the $500 million already appropriated by Congress in 2016 under the 21st Century Cures Act with the Obama administration.
Even Chris Christie, the Republican New Jersey Governor who led the White House Opioid Commission, said:
“In New Jersey, we are spending $500 million,” he said. “I am not, quite frankly, impressed with $1 billion from the federal government for the nation.”
Strict Prevention and Punishment
When you look at what she has said on record in regards to opioids and addiction, it doesn’t really inspire a great deal of confidence. Kellyanne Conway has consistently hinted to an outdated ideology of what addiction is and how to address it.
In the past, Kellyanne has said,
“The best way to stop people dying from overdoses and drug abuse is by not starting in the first place… That’s a big core message for our youth.”
That’s right; just say no.
Critics say this aligns with the mindset of Jeff Sessions and others in the White House who seem to think that ‘Just Say No’ tactics actually work, or that purely prevention-based programs like D.A.R.E. can solve the whole problem. While prevention is important, it has proven to be ineffective as a focal point when addressing addiction.
Circling back to publicity, what Ms. Conway does seem to heavily endorse is a White House investigation for a “national ad campaign” on abuse prevention. President Trump himself had voiced his own support for a national advertising initiative to try and deter drug use.
But we all remember those commercials- this is your brain on drugs- and they didn’t really help that much.
Again, it seems Attorney General Sessions and the current administration is more focused on punishment than treatment and strict law enforcement. Sessions said the Justice Department was giving more than $12 million in grants to state and local law enforcement to help them prosecute crimes connected to:
Sessions is also ordering all U.S. Attorney offices to designate opioid coordinators. Kaitlyn Boecker, Policy Manager with the Drug Policy Alliance, has been vocal in her disapproval of the current steps being taken.
“Despite declaring the opioid overdose crisis a public health emergency just last month, the Trump Administration continues to emphasize failed prohibitionist policies while ignoring proven public health measures that we know reduce overdose death, like community naloxone distribution.”
“As we feared, the Administration is using the overdose crisis as an excuse to ratchet up the war on drugs rather than an opportunity to save lives.”
At this point, we can say that the news is not without skeptics. While many are still trying to remain hopeful that maybe because Kellyanne is so vocal and such a well-known surrogate for the president that perhaps she will be able to garner more attention to the issue.
While the fight for more resources continues, we should always encourage people to seek help. There are many safe and effective treatment resources already that have been helping people recover from drug and alcohol addiction for decades, like Palm Healthcare Company. If you or someone you love is struggling, please call toll-free now. We want to help.
CALL NOW 1-888-922-5398
Support for Medication-Assisted Treatment (MAT) has continued to grow in recent years as the opioid epidemic in America has put a mounting strain on the country. While the numbers of overdoses and opioid-related deaths have steadily climbed to devastating heights there has been more effort to explore treatment options. A better understanding of the medical and mental health aspects of addiction has become a priority. Stigma has slowly begun to carry less weight while advocates push for more effective and supportive routes to care for recovering addicts. One thing people have turned to heavily is medications like Suboxone of Methadone in attempts to steer away from more illicit and dangerous substances like heroin or fentanyl.
The application of medication in treatment can be very useful. It is a strategy that can help with the preservation of life by helping people stay off more unpredictable and life-threatening substances. However, some would say that if used for long-term this form of treatment is still relying on the idea of substitution. Often times these drugs have their own very harsh withdrawal symptoms, especially with extended use.
Taking a look at the more popular drugs used for medication-assisted treatment, one may ask- can you quit medication-assisted treatment with no withdrawals?
Understanding Medication-Assisted Treatment
Medication Assisted Treatment is the use of anti-craving medications to try and help address issues related to drug dependence, withdrawal, and relapse. The more common medications used in MAT include:
But MAT is also utilized alongside comprehensive therapy and other forms of support. Experts and advocates for addiction recovery, including the Substance Abuse and Mental Health Services Administration (SAMHSA), insist that maintenance medications alone are not sufficient enough treatment.
Advocates for medication-assisted treatment will compare MAT to someone taking medication for diabetes or asthma, with the belief that maintenance drugs are an essential part of staying healthy. However, others in the world of addiction recovery still believe it is possible to be healthy in recovery without the prolonged use of powerful medications.
The truth is the answer may not be the same for everybody. Different treatments may be more useful for different people. No one should be ashamed of the method they use to get help. But we also want to look at how some drugs used in medication-assisted treatment might make things more complicated for certain people.
Looking at the most popular maintenance drugs for opioid addiction, of course, we find Suboxone. To better understand Suboxone withdrawals, we first have to know what it is. This popular brand name is used to identify a prescription medication that contains active ingredients:
- Buprenorphine- a narcotic opioid medication
- Naloxone– an opioid blocker that impedes the effect of opioid medications
This medication functions as a partial opioid agonist and diminishes cravings as well as prevents other opioids from reacting to the brain’s opioid receptors. Taken in low doses for short periods of time, the drug can be helpful in curbing opioid withdrawal symptoms while tapering off without too many residual effects.
The tricky part comes when someone uses Suboxone for an extended amount of time as a replacement for heroin or other opioids.
Sometimes this can lead to its own form of recreational use and physical dependence. Even the U.S. Drug Enforcement Administration reports that Suboxone is commonly susceptible to abuse. It is still a powerful drug.
Suboxone Withdrawal Symptoms
While Suboxone and other maintenance drugs may be a preferred tactic for going ‘cold turkey’ off of heroin or other opioids, the drug itself still has the power to cause its own set of withdrawal symptoms. These symptoms can include:
- Irritability or agitation
- Difficulty sleeping
- Profuse sweating
- Runny nose
- Frequent yawning
- Stomach pain or cramping
- Dilated pupils
- Nausea and vomiting
- Changes in mood
Not to mention precipitated withdrawal, when the ingredients in this medication can actually induce the onset of unpleasant symptoms rapidly, if not immediately, for someone actively engaged in opioid use.
Methadone is a long-acting opioid medication utilized since the 1970s to try and help people get off of heroin. It is typically used today under strict medical supervision because the drug is very potent and has a high risk of addiction. In fact, a 2012 National Survey on Drug Use and Health found that approximately 2.46 million people reported to using methadone for a non-prescribed purpose at least once.
According to another study, in 2009 methadone was responsible for 1 out of every 3 opioid overdose deaths.
Because of the risks, a gradual taper should be utilized to wean someone off of methadone. Often times doctors will prescribe another detox medication to help with this process, with the tapering to be done under medical supervision.
But as with trying to quit heroin or other powerful opioids ‘cold turkey’, trying to abruptly discontinue methadone can bring on intense withdrawal. This includes physical and psychological symptoms such as:
- Runny nose
- Tearing or watery eyes
- Muscle aches
- Joint pain
- Abdominal cramps
Many of these symptoms are similar to the symptoms of withdrawing from heroin or other opioids. So in a sense, this drug can create similar withdrawal symptoms as the drugs it is supposed to be used to treat.
Quitting Medication Assisted Treatment
Is it possible to quit medication-assisted treatment- yes, there are always other options for getting comprehensive care and lasting recovery without the prolonged use of these medications. Even relapse prevention is possible without relying on medications to fight cravings.
Can you quit medication-assisted treatment with no withdrawals? Well, that may be a process. It depends on a number of factors, such as the specific maintenance medication and the length of time using it. For example, someone who has been using methadone for years could probably have a much harder time getting off methadone than someone who used another medication for a month or so to help get off opioids.
Safety is crucial when deciding to quit MAT. Quitting medication-assisted treatment without a taper or other forms of medication can cause intense withdrawals. It is not suggested that someone try to quit MAT ‘cold turkey’ or without consulting a doctor for help with changing the dosage and slowly tapering off the drugs.
Again, just because it isn’t heroin or fentanyl doesn’t make it harmless.
MAT or Detox?
Medication-assisted treatment holds a lot of value, but the question becomes whether or not it is the kind of sustainable solution you want. Recovery isn’t one-size-fits-all. Medication-assisted treatment can be helpful in saving someone’s life who cannot stop using drugs. But is it something that will completely eliminate cravings and withdrawals, or will it just postpone these symptoms?
Remember, these are still powerful narcotic drugs that have a high risk for abuse. Some people end up using medication maintenance for life. Others will use it for a short period of time, with a detox period afterward. Either way, it is your choice; how long do you want to rely on substances, and to what extent?
Other models believe in providing holistic treatment and personalized therapy after a detox period, helping to reduce and remove chemical dependence and build a foundation for personal recovery.
Using medication to help with the painful and often overwhelming symptoms of withdrawal from opioids and other drugs can be essential to a smooth and healthy transition. In fact, with a safe medical detox, each individual is given an initial assessment to see what medications will be helpful in making this phase of treatment comfortable and safe. This can include medications for anxiety, mood disorders, physical pains and various other side-effects of substance abuse.
And when it comes to some of these medications, it can sometimes be necessary to continue using them.
The biggest difference is whether narcotic maintenance medications like Suboxone or methadone become a long-term prerequisite to recovery, or if they are used to help someone who is sick get better so that the real healing can happen.
Palm Healthcare Company believes in providing a safe medical detox to allow for a comfortable and healthy transition from active drug or alcohol use. Our facilities utilize an experienced and professional medical staff who help to monitor each individual’s progress and provide effective medical support for lasting recovery. If you or someone you love is struggling with substance abuse or addiction, please call toll-free now. We want to help.
CALL NOW 1-888-922-5398
While the nation is still struggling to find the right strategy to climb out of the opioid crisis in U.S. it seems many are holding onto the idea that Big Pharma is going to save us from the destruction they helped create. While we can agree that evidence-based medical assistance in recovery is a useful tool, some seem to think that the only fix for a pill problem is more pills, or in this case, more needles.
Just recently, after President Trump declared the opioid crisis a “National Health Emergency”, the advisory committee to the U.S. Food and Drug Administration (FDA) voted 18-1 that a new injectable drug called RBP-6000 could benefit addicts and the lower of two doses studied had an “acceptable” safety profile.
So what does this mean for the opioid epidemic efforts? Is Indivior a miracle injection that is going to make the epidemic more manageable, or is it another kind of Methadone or Suboxone that is just keeping people hooked?
What is RBP-6000?
For a little background, RBP-6000 is an experimental drug designed to help fight America’s growing opioid addiction crisis. It is described as a sustained-release buprenorphine. It is designed to be delivered once a month as a subcutaneous injection. The compound solidified once in contact with bodily fluids and releases buprenorphine over time.
If approved, it will be the first monthly injectable buprenorphine treatment. When creating the drug the manufacturers studied two dosing regimens.
In one, 300 milligrams were given once a month for six months.
In the other, two doses of 300 milligrams were followed by four doses of 100 milligrams.
According to reports, there was only a minute difference in effectiveness between the two doses, and they drug company acknowledge that the higher dose of RBP-6000 caused more side effects. Looking closely into some of the reports from the research, some side-effects include:
Injection site pruritus
Upper respiratory tract infection
While these side effects were not noted in an extremely high percentage of those tested, they are still relevant to consider until there is more extensive data available. So far, the report says the safety profile is consistent with that of Suboxone.
So RBP-6000 is like Suboxone using the delivery of Vivitrol; another injectable drug used to try and block the effects of opioids.
Big Pharma Making Big Moves
This is one sign of how Big Pharma is stepping in to make a buck off of the opioid epidemic yet again.
Indivior is the company behind RBP-6000. It was originally part of Reckitt Benckiser as the Buprenorphine division but has since split off to be a specialty pharmaceutical company. Indivior already sells Suboxone Film, a product which combines buprenorphine and naloxone. Suboxone is a maintenance drug widely used in America to try and curb the effects of opioid addiction and withdrawal, but Suboxone is known to have its own side-effects and withdrawals. Some even attest that Suboxone is itself addictive and very difficult to get off of.
Two months ago the share prices for Indivior took a deep hit after a U.S. court ruling clearing the way for a generic rival to Suboxone Film. So, with new competition on the way in the Suboxone market, Indivior put a renewed focus on another maintenance drug to bring to market.
Some analysts already expect that RBP-6000 could capture around 30% of the broader buprenorphine market. Some believe this new form of injectable buprenorphine could generate annual sales of around $700 million by 2021.
Jefferies sees potential sales of $1.3 billion by 2025.
So now the push for this new drug is boosting its sales prospects as competitors threaten revenues from Suboxone sales.
To learn more about why Suboxone isn’t the easier answer some people think it is, download our FREE E-BOOK
“5 Things No One Tells You About Suboxone”
DOWNLOAD FREE E-BOOK
Waiting for FDA Final Ruling
This endorsement on behalf of RBP-6000 comes less than a week after FDA Commissioner Scott Gottlieb announced the agency’s plans to promote extensive use among opioid addicts of less harmful opioids such as methadone and buprenorphine, the active ingredient in RBP-6000.
However, some of the FDA panelists still would like to see more data about which patients should be given the higher dose. Other panelists say they would like to have it available, even though they lack of data supporting any additional benefit of higher doses. So even though the drug is shown to have side-effects in higher doses, and there is limited information on how these side-effects impact the individual, the FDA is considering to let this drug pass the grade.
The FDA’s decision is set to be made by November 30th, although typically the agency follows the recommendations of its advisory panels. So it may very well already be a done deal.
Why It Matters
Again, with respect to the importance of offering alternatives to particularly dangerous opioids like heroin or fentanyl. It is important to have resources for the purpose of preserving of life. Keeping people alive long enough to get help is crucial. But we also have to see that this is not a miracle cure.
Methadone, Suboxone, and Vivitrol may serve a purpose for some in a certain capacity. However, these drugs are not an adequate substitute for comprehensive addiction treatment. Each one of these methods should be accompanied by a holistic treatment plan that addresses all aspect of addiction, including emotional and mental health.
Drugs like RBP-6000 may help subdue the more serious symptoms from the physical side of addiction, but they can also present their own risks.
It is important to offer safe medical assistance, but we have to remember that these Big Pharma companies are not selling us instant cures to opioid addiction. This isn’t even the first time we have seen a new drug come out to try and treat the opioid problem from companies that are closely related or directly responsible for narcotic medications that helped fuel the issue.
Remember, there is not a quick fix for this problem. We cannot prescribe our way out of the problem. It is going to take better treatment resources beyond more medications.
Drugs like RBP-6000 from Indivior are not necessarily a bad thing, but they also may not be the kind of treatment people should focus on. Instead, there are safe medical treatment options that offer holistic resources and mental health services. A lasting recovery begins with effective treatment. If you or someone you love is struggling, please call toll-free now.
CALL NOW 1-888-922-5398
In December of 2016, the Palm Partners Recovery Center blog covered a story about how federal prosecutors were bringing racketeering charges against several employees of Insys Therapeutics Inc. The initial report and the controversy that followed was a profound moment considering criminal charges are rarely ever brought against pharmaceutical companies. Now it seems that even more the corporate drug dealers who helped create the opioid crisis in America are going to be finding themselves under serious scrutiny for their unethical practices.
Last week President Trump declared the opioid epidemic a public health emergency. That very same day, as if to accent the severity of the crisis and the unignorable need for change, the co-founder of Insys Therapeutics Inc. himself was arrested on fraud and racketeering charges.
Insys Therapeutics CEO Taking a Fall
John Kapoor is the former CEO of Insys Therapeutics; a founding father of one of the most prominent opioid manufacturing companies in America. As of last week, Kapoor is reported to be charged with conspiring to push the company’s signature drug for unacceptable uses through a series of bribes and kickbacks.
The drug Kapoor and his company are accused of pushing just happens to be one of the most dangerous opioids on the market, which has contributed to countless deaths across the country over the years- fentanyl.
The brand name for the product made by Insys Therapeutics Inc is Subsys. This extremely potent compound transmits the synthetic opioid fentanyl in spray form. As an opioid analgesic, people use Subsys by spraying it under the tongue for quick absorption of potent fentanyl. Technically, this drug is supposed to only be used for treating cancer patients suffering from severe pain. But according to prosecutors that is very far from the sales strategy Kapoor and his executives were using.
With recent reports showing that approximately 64,000 Americans died last year from drug overdose, and an estimated 20,100 overdose deaths linked to synthetic opioids like fentanyl, how many of those lives were impacted by the drug Insys forced onto the market with bribes?
According to the prosecution, Kapoor and several other former high-ranking executives at the company colluded to bribe doctors to write-
“- large numbers of prescriptions for the patients, most of whom were not diagnosed with cancer.”
They also allegedly-
“- conspired to mislead and defraud health insurance providers who were reluctant to approve payment for the drug when it was prescribed for non-cancer patients.”
How did they do all this?
The Insidious Work of Insys Therapeutics Inc
Back in 2016, there was the discussion of six former executives and sales-managers from Insys Therapeutics Inc. being arrested. The charges, according to the Justice Department, included:
- Conspiring to defraud health insurers
- Conspiring to bribe doctors into needlessly prescribing Subsys, the company’s fentanyl painkiller
The scam is allegedly a long list of kickback schemes, sham speaking programs, and illegitimate gifts or services.
Allegedly, doctors and nurses were paid to attend dinners at high-end restaurants. These dinners were disguised as ‘speaker programs’ that were actually described as gatherings of friends and co-workers who had no power to prescribe medications. Supposed ‘speakers’ were paid fees of up to several thousand dollars for attending these exclusive outings.
One healthcare provider reportedly received an illegal kickback to the tune of $83,000!
All of this money to bribe doctors and other healthcare professionals to prescribe Subsys, even when inappropriate. So not only were they pressuring doctors to use their product over alternatives, but also to prescribe a dangerous and potentially fatal opioid to people who didn’t even need it.
Other stories written about in Forbes include cases in:
In 2015 a nurse practitioner pleaded guilty to violating a federal anti-kickback statute by taking money from Insys to prescribe the drug to Medicare patients who did not have cancer.
A former Insys sales representative also pleaded guilty to a conspiracy to violate the anti-kickback statute by paying two doctors to prescribe the drug.
The state has filed multiple claims against Insys Therapeutics involving the pressuring prescriptions of Subsys for unapproved uses.
Doctors who have worked with the company are being investigated by states including:
U.S. attorneys in the Central District of California and the District of Massachusetts are also investigating Insys Therapeutics Inc.
Shady Gifts and Services
The buck doesn’t stop there either. It wasn’t just cash gifts for unethical practices. Insys Therapeutics wanted their partners in crime to get the full effect of their illicit activities.
The company would send its own employees to work in doctor’s offices when the physician prescribed their fentanyl fuming drug to patients. They even hired the relatives of health care providers as a favor to the family for their loyalty to Subsys.
They allegedly even set up a portion of their staff to defraud insurance companies by calling to speak with insurance representatives while posing as doctors. Some allegations state they were even misrepresenting a patients diagnosis to inflate drug sales.
A December of 2016 indictment states that Insys actively worked to defraud insurance companies by setting up the “reimbursement unit” dedicated to obtaining prior authorization from insurers and pharmacy benefit managers.
Other Insys Therapeutics Exes
Kapoor stepped down as chief executive in January. However, he is definitely not the only former Insys Therapeutics executive currently under fire. This is just the tip of a very rocky ice-berg. The indictment from 2016 included:
Michael L. Babich
Former CEO and President of the company from Scottsdale, Arizona
Former Vice President of Sales from Charlotte, North Carolina
Richard M. Simon
Former National Director of Sales from Seal Beach, California
Former Regional Sales Director from Bryant City, Michigan
Joseph A. Rowan
Former Regional Sales Director from Panama City, Florida
Michael J. Gurry
Former Vice President of Managed Markets from Scottsdale, Arizona
On January 5, 2017, all of these defendants appeared in federal court for their initial appearance and arraignment. Each has pled not guilty and been released on conditions approved by the court. A Status Conference hearing followed on September 12, 2017 that is the first of many to be held over several months. That day Massachusetts federal judge set a trial date for October 15, 2018, for the 6 executives.
For now, we have to wait and see if any of the dirty laundries from these alleged white-collar criminals come out in the wash.
Holding Big Pharma Accountable
For a long time, Big Pharma companies have been using unlawful and corrupt tactics for marketing and distribution, which many now see has brought with it some great devastation to communities across the nation. Now, during an opioid crisis that has claimed tens of thousands of lives a year, for several years, these discretions are finally catching up to those accused of corporate greed. The DEA, FBI and Justice Department, along with several state officials and district attorneys, are now aggressively pursuing charges against Big Pharma operators who have a connection to some of the most dangerous and widely abused narcotics on the market.
The acting U.S. Attorney William D. Weinreb said in a statement,
“In the midst of a nationwide opioid epidemic that has reached crisis proportions, Mr. Kapoor and his company stand accused of bribing doctors to overprescribe a potent opioid and committing fraud on insurance companies solely for profit.
“Today’s arrest and charges reflect our ongoing efforts to attack the opioid crisis from all angles,”
Kapoor was arrested in Arizona and his indictment was filed in federal court in Boston. Prosecutors say the charge of conspiracy to violate the anti-kickback law carries the possibility of up to five years in prison. However, the charges of conspiracy to commit racketeering and conspiracy to commit mail and wire fraud each carry a maximum sentence of up to 20 years in prison. Needless to say, Mr. Kapoor is in for a fight.
But many are still wondering if these executives will truly be held accountable? And truthfully, is it even enough at this point? Even if proven to be indirectly contributing to the opioid epidemic, how could anyone ever know how many lives were damaged or lost because the powerful played around with lethal prescription drugs to line their pockets?
For more important information on the dangers of prescription drugs, download our FREE E-BOOK “Big Secrets of Big Pharma: Why They Secretly Hope You Get Hooked”
DOWNLOAD FREE E-BOOK
With recent reports showing that approximately 64,000 Americans died last year from drug overdose, and an estimated 20,100 overdose deaths linked to synthetic opioids like fentanyl, how many of those lives were impacted by drugs like Subsys being forced onto the market with bribes?
More needs to be done to stop Big Pharma companies like Insys Therapeutics Inc from exploiting the system and putting the lives of millions of Americans at risk. And not just the middle-men should be accountable, but also those sitting comfortably at the top these industries. At least this is a start. But for the individual, it all starts with taking action. Getting safe and effective treatment can not just save a life, but help someone build a foundation for a better one. If you or someone you love is struggling, please call toll-free now. We want to help.
CALL NOW 1-888-922-5398
If that headline seems kind of confusing, don’t worry, it should. Technically insurance companies are already required by law to provide the same coverage for substance abuse and mental health that they do for other health conditions… and therein lies the issue.
Back in August the White House Opioid Commission, established by President Trump and led by New Jersey Governor Chris Christie, made several recommendations to the current administration about how to address the current drug crisis as it damages communities across the country. One of those recommendations was to declare a national emergency, while others had to do with options for prevention and education.
In the aftermath of ex-DEA agent Joe Rannazzisi’s eye-opening interview exposing the shady connections between Congress and Big Pharma companies, many have been looking closely at how government officials and multi-billion dollar empires helped create the opioid epidemic. Now the White House’s Opioid Commission is putting a focus on how health insurance companies and the flaws in their policies have contributed to the intensifying addiction crisis.
So with the opioid commission saying they will call-out insurers and make demands on coverage for addiction treatment, will more people have access to help?
Restricted Addiction Treatment
One of the biggest issues the opioid commission seems to have with insurance companies is that frequently their policies only cover one type of addiction treatment and not others. It seems insurance companies are convinced that with a complex and extremely personal issue like substance use disorder or mental health conditions, there is a one-size-fits-all answer. Sadly, most advocates can tell you this isn’t the case.
Something else especially frustrating is that laws already exist to prevent insurers from treating addiction treatment different than any other health issue. Chris Christie himself said,
“Why are we still not seeing addiction services covered, and mental health services covered as broadly as every other type of disease?”
“And what do we need to do to make sure that the law is enforced and followed?”
The Mental Health Parity and Addiction Equity Act of 2008 requires health insurers to treat mental health and substance abuse disorders the same as any other disease. It means they should provide health care coverage for these conditions without additional limits, co-pays or deductibles. If companies add on additional requirements, it creates even more barriers between the suffering individual and treatment. Sadly, not every insurance company thinks it has to play by the rules.
A task force convened by President Barack Obama last year reported that numerous insurance companies still place a number of limits on addiction coverage, like more strict pre-authorization requirements. The insurance companies claim that their policies are only part of a complex problem, insisting that the issue also has to do with shortages of doctors and poor medical training from healthcare providers in the field of addiction treatment.
However, the simple fact that insurance companies are still trying to push back against supporting addiction treatment has the opioid commission ready to address the inconsistencies that are making it even harder for people who need help to get the help they deserve.
Holding Insurance Companies Accountable
The opioid commission is not holding back when it comes to trying to make insurance companies contribute to solutions since they helped contribute to the problem. The New Jersey Governor warned health insurance companies to be prepared for a final report that will “place new demands” on health insurance policies.
Christie and the opioid commission seem to be playing offense, saying Big Pharma drug companies and health insurers profit while allowing an epidemic of addiction to continue, but these new demands will hopefully change all that. Christie added,
“I’m a capitalist. I want everybody to make profits. I think it’s great. But we can’t any longer go about addressing this problem this way,”
“I hope you’re prepared to accept the challenge, because we know if it hasn’t gotten into your own house yet, it could, and then all the sudden your perspective on this problem could become markedly different.”
Not only is there more pressure on insurance companies when it comes to treatment options in their policies, but with how they handle medications in the first place.
Health insurance providers are also under a greater deal of scrutiny for policies that sometimes favor powerful and addictive painkillers over less addictive, and more expensive, variations. So not only are they limiting the options when it comes to getting treatment for substance abuse, but they are limiting coverage of medications to more addictive drugs to save money.
Insurance providers did show up to testify at the commission to help create a more comprehensive view of the issue. Involved were executives from some of the nation’s largest insurance companies:
- Blue Cross Blue Shield
- Harvard Pilgrim Health Care
- Kaiser Permanente
- UnitedHealth Group
- UPMC Health Plan
Representative Elijah Cummings, the ranking member of the House Oversight Committee, also has questions for many of those same companies. Some of these inquiries stem from a report by The New York Times last month stating insurance companies “erected more hurdles to approving addiction treatments than for the addictive substances themselves.”
Cummings wrote letters to seven of the companies which state,
“This is not a hypothetical problem. The over-prescription of opioids leads to addiction and death.”
The White House’s opioid commission has also spoken with leaders in the pharmaceutical industry. All this shows that the opioid commission is not only worried about exploring our options for fixing the issue but also in examining all the elements that helped cause the opioid epidemic in America. Christie says the final report to President Trump will include sweeping recommendations but will also be “extraordinarily instructive in terms of how we got here, which is an important thing for this commission to acknowledge.”
The commission will hold its last meeting November 1st before delivering its final report to the President. Only time will tell what demands this report plans to place on insurance companies to provide more coverage for addiction treatment services.
Will Insurance Companies Change?
The big question becomes how will this impact the services offered by insurance companies. Will the opioid commission’s suggestions help shape new policies, or will some insurance companies continue to ignore the parity laws put in place to make sure they do not discriminate against the treatment of substance abuse?
Will these changes allow for the coverage of different innovative and holistic treatment options, or will the change only support programs that depend on maintenance drugs like methadone or Suboxone?
Hopefully, the new demands being put on insurance companies will help to support mental health and substance abuse parity. When it comes to addressing addiction in America, we need every resource we can get in order to move forward with overcoming the opioid epidemic. With more officials taking a closer look at every aspect of the issue, perhaps we can get a more effective strategy for addressing the problem.
With so many people struggling with opioids and other drugs across the country, comprehensive and effective treatment is essential to making any real progress. For decades Palm Healthcare Company facilities have been providing holistic addiction treatment options that help create lasting change. If you or someone you love is struggling with substance abuse or addiction, please call toll free now.
CALL NOW 1-888-922-5398
Back in August, the Commission on Combating Drug Addiction and the Opioid Crisis began urging President Trump to declare a national public health emergency to combat the opioid crisis that has crippled countless communities around America. While the President did soon enough say that he believed the opioid epidemic was indeed a national emergency, the actual official process has yet to begin. However, just this week news broke that President Trump will soon formally declare the “national emergency” status of the opioid crisis.
Reports indicate President Trump plans to make the official declaration next week. It seems appropriate following the explosive exposé following the story on ’60 Minutes’ of former DEA agent Joe Rannazzisi pointing a finger at Big Pharma companies, Congress, and lobbyists for fueling the opioid epidemic.
In fact, Republican Representative Tom Marino, who was the top pick for the Trump administrations Drug Czar, was name-dropped in a less than flattering light in the ’60 Minutes’ piece. Reports today now show Marino has withdrawn from consideration following the story.
So what does this newest revelation mean for combatting the opioid crisis?
One of the initial reasons for declaring a national emergency is pretty straight-forward; raising awareness. Not that we don’t see enough shocking news stories or warnings from local officials being issued in various states, but more attention on the issue will help channel more resources into actually helping address it.
As the commission states in their report:
“It would also awaken every American to this simple fact: if this scourge has not found you or your family yet, without bold action by everyone, it soon will,”
“You, Mr. President, are the only person who can bring this type of intensity to the emergency, and we believe you have the will to do so and to do so immediately.”
When the President of the United States says something is a priority, people take notice. Regardless of whether people always agree on politics, when we can all get behind a major issue and put effort into a more inclusive conversation, there is a better chance more can be done.
Overcoming Addiction Stigma
One of the most important aspects of fighting addiction is overcoming the addiction stigma itself. Many people who are suffering do not get the help they need because they are afraid of the stereotypes associated with drug abuse. A lot of people still doubt what the majority of the medical and scientific communities have adopted as fact; that addiction is a health issue, not a moral failing.
By declaring the opioid crisis a national emergency, President Trump has an opportunity to promote education along with public awareness. The more we can help people to understand how addiction affects the mind and body, the better odds we have of supporting those struggling with compassionate and effective treatment options.
Funding for Fighting Opioids
Perhaps one of the biggest hopes for many addiction recovery advocates is that by President Trump declaring the opioid crisis a national emergency he will influence lawmakers to allocate more funding to resources combatting addiction.
A federal declaration would also allow the government to pull funding from other areas as well, such as funding used for the Public Health Emergency Fund, or even the federal Disaster Relief Fund. So while America has been struck pretty hard by hurricanes and natural disasters, some of this same funding may end up going toward creating addiction resources.
One thing many are hoping is that these new funds will also go to promoting more addiction treatment options across the country. Some states may pursue incentives for performance-based enhanced care management (ECM) program, like one recently implemented in New Jersey. Others may put those resources into prevention and education initiatives.
One thing should seem pretty clear; treatment options should be a priority. We already know we cannot arrest our way out of this problem. The War on Drugs did not work, and many do not expect it will now either. With President Trump declaring the national emergency, hopefully, the new effort will go into protecting mental health and substance abuse parity with healthcare and insurance providers. If we have more ways to help those already desperately in need, we could see a better chance for a way out.
With the CDC stating an estimated 91 Americans dying every single day from opioid-related death, which many experts believe is grossly underreported, helping more people fighting opioid addiction find a way out is crucial. However, we should not wait on politicians, health officials or anyone else to fix it. Recovery takes action. If you or someone you love is struggling, please call toll-free now. We want to help.
CALL NOW 1-888-922-5398